In this regard the Commission notes that the beneficiaries under the scheme trade with pharmaceutical products and that there is strong competition among market participants in the pharmaceutical sector. As such, the advantage granted to the beneficiaries under the scheme is likely to distort competition.
77 6. ASSESSMENT › 6.1. Existence of aid › Distortion of competition and intra-Union trade, Decision_act (EU) 2015/1300
In forcesince 27 Mar 2015